Compounds > antipyrine

antipyrine and montelukast

antipyrine has been researched along with montelukast in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH1
Fang, SH; Shi, WZ; Wei, EQ; Zhang, YM; Zhao, R1

Other Studies

5 other study(ies) available for antipyrine and montelukast

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
    Pharmacology, 2005, Volume: 73, Issue:1

    Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; Cyclopropanes; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Leukotriene Antagonists; Mice; Nervous System; Neuroprotective Agents; Psychomotor Performance; Quinolines; Receptors, Leukotriene; Sulfides; Survival Analysis; Time Factors

2005
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:4

    Topics: Acetates; Administration, Oral; Animals; Antipyrine; Atrophy; Behavior, Animal; Brain Injury, Chronic; Chromones; Cyclopropanes; Disease Models, Animal; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavengers; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Leukotriene Antagonists; Male; Mice; Mice, Inbred ICR; Nerve Degeneration; Quinolines; Rats; Rats, Sprague-Dawley; Sulfides

2011